Clinical Trial: Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Study Status: Completed
Recruit Status: RECRUITING
Condition: Large Cell Lymphoma, Diffuse
Study Type: INTERVENTIONAL
Official Title: A Phase II Trial Evaluating Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Brief Summary:
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab.Each cycle will last 21 days.GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Day 1, and dexamethasone 40 mg orally on Days 1 through 4. Epcoritamab will be administered subcutaneously (SC) on Days 1, 8, and 15.Patients will receive granulocyte colony stimulating factor (G-CSF) on Day 9 or 10 of each cycle of combination therapy.Patients will then…
Read more